Both companies will work to revolutionize cell culture media in biotech and the vaccine industry with animal-free, high-yield ...

Precision Medicine Group, a provider of next-generation drug development, CRO and commercialization services, has appointed Eric Hodgins as its Chief Information and Technology Officer, overseeing all ...

Bristol Myers Squibb’s Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients with ...

Thermo Fisher Scientific Inc. has introduced the 5L DynaDrive Single-Use Bioreactor, expanding the company's portfolio of ...

Lifecore Biomedical Inc., a fully integrated contract development and manufacturing organization (CDMO), has appointed Thomas ...

Lonza will serve as a CMAC Translation to Industry Collaborator, reinforcing its commitment to advancing innovative ...

Intas Pharmaceuticals has completed its acquisition of the UDENYCA (pegfilgrastim-cbqv) business from Coherus BioSciences Inc ...

Boehringer Ingelheim and Cue Biopharma Inc. have joined forces to develop and commercialize Cue Biopharma’s CUE-501 product candidate.

Novartis, an innovative medicines company, has announced plans to invest $23 billion over 5 years in U.S.-based ...

Wyatt McDonnell of Infinimmune shares insight on human-first models and what the FDA's policy shift means for biotech R&D.

Vanessa Zann and Andrew Parker share insights on poorly soluble APIs, approaches for modified release formulation development, and navigating accelerated approval pathways.

The U.S. Food and Drug Administration has designated Celltrion Inc.’s YUFLYMA (adalimumab-aaty), as an interchangeable biosimilar to Humira.